GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LTR Pharma Ltd (ASX:LTP) » Definitions » Net Income Including Noncontrolling Interests

LTR Pharma (ASX:LTP) Net Income Including Noncontrolling Interests : A$-1.46 Mil (TTM As of Jun. 2023)


View and export this data going back to 2023. Start your Free Trial

What is LTR Pharma Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

LTR Pharma's Net Income Including Noncontrolling Interests for the six months ended in Jun. 2023 was A$-1.46 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Jun. 2023 was A$-1.46 Mil.

LTR Pharma Net Income Including Noncontrolling Interests Historical Data

The historical data trend for LTR Pharma's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LTR Pharma Net Income Including Noncontrolling Interests Chart

LTR Pharma Annual Data
Trend Jun21 Jun22 Jun23
Net Income Including Noncontrolling Interests
-0.04 -1.03 -1.46

LTR Pharma Semi-Annual Data
Jun21 Jun22 Jun23
Net Income Including Noncontrolling Interests -0.04 -1.03 -1.46

LTR Pharma Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Jun. 2023 was A$-1.46 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LTR Pharma Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of LTR Pharma's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

LTR Pharma (ASX:LTP) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LTR Pharma Ltd (ASX:LTP) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
Traded in Other Exchanges
N/A
Address
9A/204 Alice Street, Brisbane, QLD, AUS, 4000
Website
https://www.ltrpharma.com
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on market.

LTR Pharma (ASX:LTP) Headlines

No Headlines